Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
NCT00281125
Terminated
This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2). This study is designed to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of PTK787 when administered in combination with Pemetrexed or Pemetrexed and Cisplatin, and to characterize the safety, tolerability, biologic activity, and PK profile of PTK787 in adult patients with advanced non-small c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2012
Locations: Nevada Cancer Institute, Las Vegas, Nevada
Conditions: Non-Small Cell Lung Cancer and Pleural Mesothelioma
Register for Updates
Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
NCT00696007
Withdrawn
The purpose of this study is to test the effectiveness, safety and side effects of two chemotherapy drugs (gemcitabine and cisplatin) when combined with surgery after chemotherapy for patients with upper urinary tract cancer. The hypothesis is that undergoing chemotherapy prior to surgery will have a beneficial effect on prognosis and may improve overall survival as in patients with bladder cancer, and will allow better tolerance of chemotherapy than if it were given after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2012
Locations: Lahey Clinic, Inc., Burlington, Massachusetts
Conditions: Transitional Cell Carcinoma
Register for Updates
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
NCT00068575
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interferon alfa may interfere with the growth of the tumor cells and slow the growth of cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and interferon alfa with radiation therapy after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2012
Locations: M. D. Anderson Cancer Center at University of Texas, Houston, Texas
Conditions: Pancreatic Cancer
Register for Updates
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer
NCT00082862
Unknown
RATIONALE: Drugs used in chemotherapy, such as cisplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving low-dose interferon alfa on a metronomic (regularly timed) schedule may stop the growth of cancer by stopping blood flow to the tumor. Fever-range (above 101° F) whole-body hyperthermia kills tumor cells by heating them to several degrees above normal body temperature. Combining cisplatin, gemcitabine, and low-dose interferon alfa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2012
Locations: University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Pancreatic Cancer
Register for Updates
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
NCT00952497
Completed
The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced gastric cancer. The primary objective is to assess progression free survival (PFS) in subjects receiving telatinib in combination with chemotherapy (capecitabine and cisplatin). The secondary objectives are to assess overall survival, overall response rate, safety and tol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2012
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +10 locations
Conditions: Gastric Cancer
Register for Updates
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
NCT00215995
Completed
This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD 1839 following initial therapy with two other chemotherapy drugs, called Irinotecan (CPT-11) and Cisplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2012
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida +2 locations
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
NCT00020696
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/07/2012
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +53 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
NCT00002882
Completed
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interferon alfa plus combination chemotherapy and interleukin-2 is more effective than interferon alfa alone in treating patients with melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without combination chemotherapy plus interleukin-2 in treating patients with m... Read More
Gender:
ALL
Ages:
Between 10 years and 70 years
Trial Updated:
12/12/2011
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma, Skin Cancer
Register for Updates
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
NCT00401401
Terminated
The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2011
Locations: Oregon Health Sciences Center, Portland, Oregon +6 locations
Conditions: Head and Neck Cancer, Squamous Cell Cancer
Register for Updates
Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer
NCT00629226
Completed
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high energy x- rays to kill tumor cells. Bortezomib and cetuximab may make tumor cells more sensitive to radiation therapy. Drugs used i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/29/2011
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
NCT00505492
Terminated
Primary Objectives: 1. To test whether the addition of chemotherapy to radiotherapy improves the progression-free survival for patients with stage I, II and IIIa malignant mixed mesodermal tumor (MMMT) of the uterus. 2. To determine the acute and late toxicity profiles associated with this treatment regimen. 3. To describe the effect of this treatment regimen on the patient's quality of life.
Gender:
FEMALE
Ages:
All
Trial Updated:
09/13/2011
Locations: UT MD Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Uterine Neoplasms
Register for Updates
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
NCT00003690
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of flavopiridol plus cisplatin or carboplatin in treating patients who have advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2011
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Breast Cancer, Melanoma (Skin), Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates